Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke

NCT01287936 is registered in ClinicalTrials.gov with SanBio, Inc. as lead sponsor.

NCT NCT01287936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01287936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke
Lead sponsor
SanBio, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2011
Completion date
August 31, 2015
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic ischemic stroke